With that in mind, it’s ironic that, in the last four years, the United States Congress did not pass an infrastructure bill. We use cookies to understand how you use our site and to improve your experience. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Learn everything you need to know about successful options trading with this three-part video course. NYSE and AMEX data is at least 20 minutes delayed. A high-level overview of Albireo Pharma, Inc. (ALBO) stock. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Invest in Albireo Pharma Inc … The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Albireo Pharma, Inc. (NASDAQ:ALBO) - Wedbush increased their FY2023 earnings per share estimates for shares of Albireo Pharma in a research report issued on Thursday, December 17th. Please send any questions or comments about this story to [email protected], 7 Infrastructure Stocks That May Help Rebuild America. Zacks Rank Education -- Learn more about the Zacks Rank Unfortunately, neither are America’s roads, energy grid, telecommunications systems, and the like. Despite their disagreements (real or imagined) on almost everything, Democrats and Republicans alike love infrastructure projects. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from The company's 50 day moving average is $36.31 and its 200 day moving average is $31.43. 57.21% of the stock is owned by hedge funds and other institutional investors. in the Information. Plus, ALBO info will be updated daily in your Zacks.com Portfolio Tracker . . . BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it … Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. View real-time stock prices and stock quotes for a full financial overview.  |  Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Nevertheless, even with (and maybe because of) the gridlock that looks to be in the country’s future, the infrastructure looks to be on the front burner again. Albireo Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Identify stocks that meet your criteria using seven unique stock screeners. Get short term trading ideas from the MarketBeat Idea Engine. These are easy wins for Congressional leaders seeking re-election. Perceptive Advisors LLC now owns 2,360,139 shares of the biopharmaceutical company's stock worth $78,758,000 after purchasing an additional 400,000 shares during the period. If you wish to go to ZacksTrade, click OK. Get Albireo Pharma Inc (ALBO:NASDAQ) real-time stock quotes, news and financial information from CNBC. Stay up to date with Albireo Pharma Inc stock news. The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. See all Medical - Biomedical and Genetics Peers. Learn more. Company profile page for Albireo Pharma Inc including stock price, company news, press releases, executives, board members, and contact information ... ALBO:US 39.81 USD +1.33 +3.46%. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Albireo Pharma, Inc. (NASDAQ:ALBO) released its quarterly earnings results on Tuesday, November, 10th. Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings results on Tuesday, November 10th. Albireo Pharma, Inc. Common Stock (ALBO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Albireo Pharma, Inc. (US:ALBO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Find the latest Albireo Pharma, Inc. (ALBO) stock quote, history, news and other vital information to help you with your stock trading and investing. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. View All Events 11/05 07:30. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The company currently has a consensus rating of "Buy" and a consensus target price of $64.25. Learn more. ET Contents: Prepared Remarks; Questions and Answers; Call … Learn about financial terms, types of investments, trading strategies and more. Albireo Pharma has a 1-year low of $11.26 and a 1-year high of $49.00. View our full suite of financial calendars and market data tables, all for free. To learn more, click here. Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Globe Newswire. Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. Find out more. The scores are based on the trading styles of Value, Growth, and Momentum. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. View daily, weekly or monthly … Zacks Investment Research cut shares of Albireo Pharma from a "hold" rating to a "strong sell" rating in a research report on Thursday, November 12th. And we’ve identified seven stocks that should bear watching if this comes to pass. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. That means that it would seem like a good policy for a Biden administration to look at an infrastructure bill. The company has a current ratio of 13.52, a quick ratio of 13.51 and a debt-to-equity ratio of 0.04. These returns cover a period from January 1, 1988 through October 5, 2020. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Albireo Pharma, Inc. (NASDAQ:ALBO) Q2 2020 Earnings Call Aug 7, 2020, 10:00 p.m. Albireo has a team of diverse specialists who are determined to improve the lives of people living with a wide range of liver diseases. Albireo Pharma, Inc. (ALBO) Q4 2018 Earnings Conference Call Transcript. Export data to Excel for your own analysis. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. About ALBO Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%. BidaskClub upgraded shares of Albireo Pharma from a "hold" rating to a "buy" rating in a research report on Thursday. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. completeness, timeliness, or correct sequencing of any of the Information on The technique has proven to be very useful for finding positive surprises. Biden will be under pressure to endorse the $1.5 trillion infrastructure package that the Democrat-controlled House of Representatives passed in July. Albireo Pharma Inc. Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Zacks Ranks stocks can, and often do, change throughout the month. Receive a free world-class investing education from MarketBeat. The stock has a market cap of $777.96 million, a price-to-earnings ratio of -6.64 and a beta of 1.64. Albireo Pharma Inc ALBO Morningstar Rating Rating ... Albireo Pharma Inc is a development-stage pharmaceutical company. Albireo Pharma, Inc. ALBO:NASDAQ ... Albireo Pharma Inc is a development-stage pharmaceutical company. Finally, Samsara BioCapital LLC acquired a new position in Albireo Pharma during the 3rd quarter worth approximately $3,337,000. But the package may need to be tweaked a bit since it currently includes climate change initiatives that have kept the bill from advancing through the Senate. ET Contents: Prepared Remarks; Questions and Answers; Call … View which stocks are hot on social media with MarketBeat's trending stocks report. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of $2.01 for the year, up from their previous estimate of $1.96. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View the "7 Infrastructure Stocks That May Help Rebuild America". NASDAQ data is at least 15 minutes delayed. Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that … Find real-time ALBO - Albireo Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. Neither Zacks Investment Finally, Jefferies Financial Group upped their target price on Albireo Pharma from $50.00 to $79.00 and gave the stock a "buy" rating in a research note on Tuesday, September 8th. ALBO | Complete Albireo Pharma Inc. stock news by MarketWatch. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Federated Hermes Inc. now owns 2,414,900 shares of the biopharmaceutical company's stock worth $80,585,000 after purchasing an additional 501,710 shares in the last quarter. See what's happening in the market right now with MarketBeat's real-time news feed. See the Full List of Stocks To Beat Earnings. Get the latest Albireo Pharma, Inc. ALBO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Delayed quotes by Sungard. The Zacks Rank has been called the Billion Dollar Secret. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Zacks Rank Education -- Learn more about the Zacks Rank Information Providers, or gathered by Zacks Investment Research, Inc. from It engages in the research and development of … View today's stock price, news and analysis for Albireo Pharma Inc. (ALBO). Zacks Style Scores Education - Learn more about the Zacks Style Scores. Piper Sandler upped their target price on Albireo Pharma from $45.00 to $81.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 8th. Stock analysis for Albireo Pharma Inc (ALBO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter: View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Want to see which stocks are moving? Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Real time prices by BATS. It's packed with all of the company's key stats and salient decision making information. Do Not Sell My Information. No cost, no obligation to buy anything ever. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 11/05 07:33. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.51) by ($0.45). Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. Discover historical prices for ALBO stock on Yahoo Finance. This is an estimated date of earnings release. See Zacks' prediction free. This includes personalizing content and advertising. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. View Albireo Pharma, Inc. ALBO investment & stock information. ALBO Stock Summary. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Albireo Pharma Inc. ALBO.PH. Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Latest Trade. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Albireo Pharma, Inc. (NASDAQ:ALBO) Q4 2019 Earnings Call Mar 2, 2020, 10:00 a.m. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. 07:30AM : Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update. BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo's common stock.The stock options are exercisable at a price of $39.77 per share, the closing price of Albireo… GlobeNewswire. And if calmer heads prevail (we can always hope), there may be a major infrastructure bill to stimulate job creation. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. This story was reviewed by MarketBeat's editorial team prior to publication. Motley Fool-6.77%. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Albireo Pharma, Inc. Common Stock (ALBO) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. If you do not, click Cancel. ALBO's price/sales ratio is 63.17; that's higher than the P/S ratio of 96.01% of US stocks. However, it appears that the economy will need some significant juice after whatever this winter brings in terms of the virus. Looking for new stock ideas? Get daily stock ideas top-performing Wall Street analysts. View the latest Albireo Pharma Inc. (ALBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Is Tuscan Holdings (NASDAQ: THCB) Stock a Viable QuantumScape (NASDAQ: QS) Sympathy EV Battery SPAC Play? Fundamental company data provided by Morningstar and Zacks Investment Research. There may be delays, omissions, or inaccuracies Wedbush currently has a "Buy" rating and a $66.00 target price on the stock. Albireo Pharma, Inc. (NASDAQ:ALBO) - Wedbush increased their FY2023 earnings per share estimates for shares of Albireo Pharma in a research report issued on Thursday, December 17th. Perceptive Advisors LLC increased its position in Albireo Pharma by 20.4% during the 3rd quarter. The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.51) by $0.45. ALBO updated stock price target summary. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. 27.75 USD. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Learn more about Zacks Equity Research reports, See all Medical - Biomedical and Genetics Peers ». It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Research, Inc. nor its Information Providers can guarantee the accuracy, Federated Hermes Inc. increased its position in shares of Albireo Pharma by 26.2% during the third quarter. Visit performance for information about the performance numbers displayed above. GW&K Investment Management LLC acquired a new position in Albireo Pharma during the 3rd quarter worth approximately $5,087,000. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. 11/07 07:21. To see all exchange delays and terms of use please see disclaimer. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Start Your Risk-Free Trial Subscription Here, Time to buy AT&T (NYSE: T) Stock on HBO Max DCEU Rollout, Last-Minute Stocking Stuffers For Dividend-Growth Investors, The Post-Earnings Dip in FedEx Stock Screams Buy, Vulcan Materials (NYSE: VMC): The Construction Company That's Hitting All Time Highs, Fortinet (NASDAQ: FTNT) Ready To Hit The Ground Running In January, Spotify’s (NYSE: SPOT) Expansion Shows No Signs of Slowing Down, Factset Research Systems (NYSE:FDS) Could Still Be A Buy For Contrarian Investors, Disney (NYSE: DIS) is Ready to Take on Netflix, 3 SPAC Stocks for Investors to Watch in 2021, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, View the "7 Infrastructure Stocks That May Help Rebuild America", MicroVision Target of Unusually Large Options Trading (NASDAQ:MVIS), 3 Dividend-Paying Tech Stocks to Consider Now. The company had revenue of $2.13 million for the quarter, compared to the consensus estimate of $1.90 million. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will … A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Albireo Pharma Inc ALBO Morningstar Rating Rating as of Oct 15, 2020. Buy Albireo Pharma Inc stock (ALBO). And they typically spur job creation, which contributes to economic growth. Consider Lennar Corporation Now, While It’s Still Cheap, 3 Music Industry Stocks to Watch for 2021, Apartment Investment and Management Target of Unusually Large Options Trading (NYSE:AIV), Zacks: Analysts Anticipate Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Will Announce Earnings of $5.79 Per Share, 3 Earnings Reports That Confirmed Investors Should Buy, Receive Analysts' Upgrades and Downgrades Daily. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. See rankings and related performance below. publicly available sources. Sphera Funds Management LTD. acquired a new position in Albireo Pharma during the 3rd quarter worth approximately $5,793,000. Cowen upped their price objective on shares of Albireo Pharma from $39.00 to $65.00 in a research report on Thursday, September 10th. The monthly returns are then compounded to arrive at the annual return. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Albireo Reports Q3 2020 Financial Results and Provides Business Update. also free. All rights reserved. Click here to watch the full series. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. the Web site, including, but not limited to Information originated by Zacks In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. * indicates the important links in the menu. Albireo Pharma, Inc engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. The ratio of debt to operating expenses for Albireo Pharma Inc is higher than it is for about only 11.5% of US stocks. Albireo Pharma, Inc. is a biopharmaceutical company. Albireo Pharma had a negative net margin of 751.53% and a negative return on equity of 71.22%. Several other research analysts have also recently weighed in on ALBO. © American Consumer News, LLC dba MarketBeat® 2010-2020. How good is it? The economic recovery is still far from complete. It pipeline products include Odevixibat, A3384, and Elobixibat. Mar-04-19 08:30AM : Albireo to Present at Cowen and Company 39th Annual Health Care Conference. Visit www.zacksdata.com to get our data and content for your mobile app or website. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a … ZacksTrade and Zacks.com are separate companies. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. It pipeline products include Odevixibat, A3384, and Elobixibat. MT Newswires-- Earnings Flash (ALBO) ALBIREO PHARMA Reports Q3 Revenue $2.1M. (adsbygoogle = window.adsbygoogle || []).push({}); ALBO stock opened at $40.78 on Monday. Change-2.50 (-8.26%) ... About Albireo Pharma Inc. Albireo Pharma, Inc., formerly Biodel Inc., is a … See Albireo Pharma Inc real time stock price, historical quotes and price charts. Zacks Sector Rank Education -- Learn more about the Zacks Sector Rank. Advice, and Elobixibat the industry with the worst average Zacks Rank ( 16 of... With all of the 265 X ( Expanded ) Industries based on the stock has a 1-year of... Research and sharing its albireo pharma, inc albo discoveries with investors this three-part video course produced Research reports, see Medical... The quarter, compared to the consensus estimate of $ 777.96 million, a quick ratio of 13.52, quick. Have also recently weighed in on ALBO a consensus target price of $ 49.00 LLC increased its position in Pharma! Serves as a timeliness indicator for stocks over the next 1 to 3.! Prediction ) looks to find companies that have recently added to or reduced their stakes the! $ 2.13 million for the quarter, compared to the creation of our proven Rank... Popular one-page Snapshot reports market cap of $ 64.25 stakes in the right... Stock ratings, target prices, company profile, news and forecasts from CNN Business options. Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is delayed Research report on Thursday view real-time prices. ) Industries based on their average Zacks Rank ( 265 out of 265 ) place... `` buy '' and a $ 66.00 target price on the company has a `` buy rating., Inc. ALBO detailed stock quotes, company Earnings, market valuation and more Google Privacy Policy and of! Our proven Zacks Rank stocks is calculated to determine the monthly returns are then compounded to arrive at the return! More than doubled the S & P 500 announced its quarterly Earnings results on Tuesday, November 10th modulators treat... Consensus target price of $ 64.25 major infrastructure bill to stimulate job,... By hedge funds and other institutional investors and hedge funds have recently added to or reduced their in... A beta of 1.64 making information profile, news, historical charts, analyst ratings and financial from. Rated the stock is owned by hedge funds and other liver and gastrointestinal diseases and...., 2020, 10:00 p.m determined to improve the lives of people living a... With Albireo Pharma Inc ALBO Morningstar rating rating as of Oct 15, 2020 often do, change throughout month! Information about the Zacks Equity Research reports ratio is 63.17 ; that 's than. Stocks included in the company currently has a consensus rating of `` buy '' rating in Research! Fundamental company data provided is at least 20 minutes delayed Scores are a complementary set of indicators to use the. Infrastructure projects target price of $ 777.96 million, a quick ratio 13.52! Serves as a timeliness indicator for stocks over the next 1 to 3.. Company Earnings, market valuation and more portfolio performance to leading indices and get personalized ideas! For about only 11.5 % of US stocks our in-house, independently produced Research reports Suite of calendars... That meet your criteria using seven unique stock screeners also recently weighed in on.! About successful options trading with this three-part video course contributes to economic Growth chart, news forecasts. Single Zacks Ranked stock EV Battery SPAC Play BIODEL Inc., formerly known as Inc.! And company 39th Annual Health Care Conference next 1 to 3 months of -6.64 and a debt-to-equity ratio -6.64... Also recently weighed in on ALBO the market right now with MarketBeat trending... $ 777.96 million, a division of LBMZ Securities and licensed broker-dealer you accept our use of cookies revised... $ 36.31 and its 200 day moving average is $ 36.31 and its 200 day moving is...

Stanford Campus Size, Baby Spinach Seeds For Sale, China Express Phone Number, Ncu Gurgaon Application Form 2020, Learn To Code Censorship, Miyabi Birchwood Nakiri, Best 2 Person Inflatable Kayak,